Jien-Wei Liu

Jien-Wei Liu

Auto-generated profile, based on publicly available information

Jien-Wei Liu

Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2012 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ILIng-Kit Lee
Ing-Kit Lee
JLJien-Wei Liu
Jien-Wei Liu
KYKuender D. Yang
Kuender D. Yang
A better description of the clinical and laboratory manifestations of fatal patients with dengue hemorrhagic fever (DHF) is important in alerting clinicians of severe dengue and improving management. Of 309 adults with DHF, 10 fatal patients and 299 survivors (controls) were retrospectively analyzed. Regarding causes of fatality, massive gastrointestinal (GI) bleeding was found in 4 patients, dengue shock syndrome (DSS) alone in 2; DSS/subarachnoid hemorrhage, Klebsiella pneumoniae meningitis/bacteremia, ventilator associated pneumonia, and massive GI bleeding/Enterococcus faecalis bacteremia each in one. Fatal patients were found to have significantly higher frequencies of early altered consciousness (≤24 h after hospitalization), hypothermia, GI bleeding/massive GI bleeding, DSS, concurrent bacteremia with/without shock, pulmonary edema, renal/hepatic failure, and subarachnoid hemorrhage. Among those experienced early altered consciousness, massive GI bleeding alone/with uremia/with E. faecalis bacteremia, and K. pneumoniae meningitis/bacteremia were each found in one patient. Significantly higher proportion of bandemia from initial (arrival) laboratory data in fatal patients as compared to controls, and higher proportion of pre-fatal leukocytosis and lower pre-fatal platelet count as compared to initial laboratory data of fatal patients were found. Massive GI bleeding (33.3%) and bacteremia (25%) were the major causes of pre-fatal leukocytosis in the deceased patients; 33.3% of the patients with pre-fatal profound thrombocytopenia (<20000/µL), and 50% of the patients with pre-fatal prothrombin time (PT) prolongation experienced massive GI bleeding. Our report highlights causes of fatality other than DSS in patients with severe dengue, and suggested hypothermia, leukocytosis and bandemia may be warning signs of severe dengue. Clinicians should be alert to the potential development of massive GI bleeding, particularly in patients with early altered consciousness, profound thrombocytopenia, prolonged PT and/or leukocytosis. Antibiotic(s) should be empirically used for patients at risk for bacteremia until it is proven otherwise, especially in those with early altered consciousness and leukocytosis. Fatality rate and causes of fatality in dengue-affected patients greatly varied from one reported series to another. A better understanding of the clinical and laboratory manifestations of fatal patients with dengue hemorrhagic fever (DHF) is important in alerting clinicians of severe dengue and improving management. In a retrospective analysis of 10 adults who died of and 299 survived (controls) DHF, dengue shock syndrome (DSS) alone was found in only 20% of dengue-related death, while intractable massive gastrointestinal (GI) bleeding was found in 40%, and DSS with concurrent subarachnoid hemorrhage, intractable massive GI bleeding with concurrent bacteremia, bacterial sepsis/meningitis, and sepsis due to ventilator associated pneumonia each were found in 10%. Early altered consciousness (developed ≤24 h after hospitalization), GI bleeding/massive GI bleeding and concurrent bacteremia were significantly found among the deceased patients. Our data suggest that hypothermia, leukocytosis and bandemia at hospital presentation may be warning signs of severe dengue. Clinicians should be alert to the potential development of massive GI bleeding, particularly in patients with early altered consciousness, profound thrombocytopenia, prothrombin time prolongation and/or leukocytosis. Antibiotic(s) should be empirically used for patients at risk for bacteremia until it is proven otherwise, especially in those with early altered consciousness and leukocytosis.

6 September 2006 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CLChen-Hsiang Lee
Chen-Hsiang Lee
LSLin-Hui Su
Lin-Hui Su
YTYa-Fen Tang
Ya-Fen Tang
JLJien-Wei Liu
Jien-Wei Liu
Objectives: To better understand the clinical outcomes of patients with extended-spectrum β-lactamase-producing Klebsiella pneumoniae (ESBL-KP) bacteraemia treated with either flomoxef or a carbapenem, and to evaluate the in vitro activities of these antibiotics against ESBL-KP. Methods: Retrospective analyses to identify risk factors for mortality in patients with flomoxef-susceptible ESBL-KP, especially addressing the therapeutic roles of flomoxef and carbapenem. In vitro activities of flomoxef and carbapenem against flomoxef-susceptible ESBL-KP isolates were evaluated by susceptibility testing and time–kill study. Results: Twenty-seven patients (flomoxef group, n = 7; carbapenem group, n = 20) were included. Clinical severity reflected by high Pitt bacteraemia score (≥6) was an independent risk factor for mortality (OR 13.43; 95% CI, 1.08–166.73; P = 0.043), while use of flomoxef or a carbapenem was not. The MICs of flomoxef and carbapenem indicated that the tested ESBL-KP were susceptible to these antibiotics regardless of the inoculum size of 105 or 107 cfu/mL. Time–kill study showed that these antibiotics (flomoxef 8 mg/L and meropenem 4 mg/L) each acted actively against and inhibited the regrowth of the tested ESBL-KP for at least 24 h. Conclusions: Flomoxef might be as clinically effective as a carbapenem in treating flomoxef-susceptible ESBL-KP bacteraemia.

23 August 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
SHShih-Chiang Hung
Shih-Chiang Hung
CKChia-Te Kung
Chia-Te Kung
CHChih-Wei Hung
Chih-Wei Hung
BLBer-Ming Liu
Ber-Ming Liu
JLJien-Wei Liu
Jien-Wei Liu
TLTzu-Chi Lee
Tzu-Chi Lee
Introduction: The adverse effects of delayed admission to the intensive care unit (ICU) have been recognized in previous studies. However, the definitions of delayed admission vary across studies. This study proposed a model to define `delayed admission’, and explored the effect of ICU waiting time on patients’ outcome. Methods: This retrospective cohort study included nontraumatic adult patients on mechanical ventilation in the emergency department (ED), from July 2009 to June 2010. The primary outcomes measures were 21-ventilator-day mortality and prolonged hospital stays (over 30 days). Models of Cox regression and logistic regression were used for multivariate analysis. The non-delayed ICU waiting was defined as a period in which the time effect on mortality was not statistically significant in a Cox regression model. To identify a suitable cutoff point between `delayed’ and `non-delayed’ subsets from the overall data were made based on ICU waiting time and the hazard ratio of ICU waiting hour in each subset was iteratively calculated. The cutoff time was then used to evaluate the impact of delayed ICU admission on mortality and prolonged length of hospital stay. Results: The final analysis included 1,242 patients. The time effect on mortality emerged after 4 hours, thus we deduced ICU waiting time in the ED of >4 hours as delayed. By logistic regression analysis, delayed ICU admission affected the outcomes of 21-ventilator-day mortality and prolonged hospital stay, with an odds ratio of 1.41 (95% confidence interval, 1.05 to 1.89) and 1.56 (95% confidence interval, 1.07 to 2.27) respectively. Conclusions: For patients on mechanical ventilation in the ED, delayed ICU admission is associated with higher probability of mortality and additional resource expenditure. A benchmark waiting time of no more than 4 hours for ICU admission is recommended.

20 December 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Chen-Hsiang LeeChen-Hsiang Lee
Chen-Hsiang Lee
TCTzu-Yao Chang
Tzu-Yao Chang
JLJien-Wei Liu
Jien-Wei Liu
FCFang-Ju Chen
Fang-Ju Chen
CCChun-Chih Chien
Chun-Chih Chien
Cheng-Hsien LuCheng-Hsien Lu
Cheng-Hsien Lu
Background: This study aimed to investigate the correlation of minimum inhibiting concentrations (MICs), obtained by broth micro-dilution, and clinical response in patients with cryptococcal meningitis.Methods: Using retrospective analyses covering the period 2001–2010, factors affecting clinical therapeutic cure in patients with cryptococcal meningitis 10 weeks after the start of anti-fungal therapy were identified. Specific emphasis was placed on the role of anti-fungal susceptibility.Results: Of 46 patients with cryptococcal meningitis identified, 21 were cured after 10 weeks of treatment. Overall, 12 strains (26.1%) were resistant to fluconazole (>8 μg/ml) and 8 (17.4%) had an MIC >1 μg/ml for amphotericin B. Twenty-three patients received combination amphotericin B and fluconazole as their initial antifungal therapy, 17 were given amphotericin B only, five received fluconazole only, and one received a combination of amphotericin B and flucytosine. After 2 weeks, all patients received fluconazole (400–600 mg daily for 8 weeks at least, then 200 mg daily thereafter). The presence of isolates resistant to fluconazole (MIC >8 μg/ml; 4.8% vs. 44%,p < 0.01) were statistically significant among patients who were cured. Anti-fungal susceptibility, reflected by fluconazole MIC >8 μg/ml, was an independent predictor of therapeutic cure at 10-week evaluation (OR = 15.7; 95% CI: 1.8-135.9;p = 0.01), but higher MIC of amphotericin B (>1 μg/ml) was not.Conclusions: The MICs of fluconazole, determined by the CLSI method, may be a potential predictor of therapeutic cure in patients with cryptococcal meningitis.

18 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LSLi-Hsiang Su
Li-Hsiang Su
ICI-Ling Chen
I-Ling Chen
YTYa-Fen Tang
Ya-Fen Tang
JLJen-Sin Lee
Jen-Sin Lee
JLJien-Wei Liu
Jien-Wei Liu
Incidence rates of healthcare-associated infections (HAIs) depend upon infection control policy and practices, and the effectiveness of the implementation of antibiotic stewardship. Amongst intensive care unit (ICU) patients with HAIs, a substantial number of pathogens were reported to be multidrug-resistant bacteria (MDRB). However, impacts of ICU HAIs due to MDRB (MDRB-HAIs) remain understudied. Our study aimed to evaluate the negative impacts of MRDB-HAIs versus HAIs due to non-MDRB (non-MRDB-HAIs). Among 60,317 adult patients admitted at ICUs of a 2680-bed medical centre in Taiwan between January 2010 and December 2017, 279 pairs of propensity-score matched MRDB-HAI and non-MRDB-HAI were analyzed. Between the MDRB-HAI group and the non-MDRB-HAI group, significant differences were found in overall hospital costs, costs of medical and nursing services, medication, and rooms/beds, and in ICU length-of-stay (LOS). As compared with the non-MDRB-HAI group, the mean of the overall hospital costs of patients in the MDRB-HAI group was increased by 26%; for categorized expenditures, the mean of costs of medical and nursing services of patients in the MDRB-HAI group was increased by 8%, of medication by 26.9%, of rooms/beds by 10.3%. The mean ICU LOS in the MDRB-HAI group was increased by 13%. Mortality rates in both groups did not significantly differ. These data clearly demonstrate more negative impacts of MDRB-HAIs in ICUs. The quantified financial burdens will be helpful for hospital/government policymakers in allocating resources to mitigate MDRB-HAIs in ICUs; in case of need for clarification/verification of the medico-economic burdens of MDRB-HAIs in different healthcare systems, this study provides a model to facilitate the evaluations.

1 June 2005 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
CLChen-Hsiang Lee
Chen-Hsiang Lee
HLHsieh-Shong Leu
Hsieh-Shong Leu
TWTing-Shu Wu
Ting-Shu Wu
LSLin-Hui Su
Lin-Hui Su
JLJien-Wei Liu
Jien-Wei Liu